Advanced Medical Solutions’s $25 Million Acquisition of Sealantis Limited

Goodwin advised Advanced Medical Solutions Group plc on the deal

Advanced Medical Solutions Group plc (AIM: AMS) executed the acquisition of Sealantis Limited for $25 million (approximately £19 million) in cash with royalties due until December 2027 on sales of any of its products that are currently in development.

Established in 1991, Advanced Medical Solutions Group is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include tissue adhesives, sutures, haemostats, silver alginates, alginate and foams which it markets under its brands; LiquiBand®, RESORBA® and ActivHeal®, as well as supplying under white label.

Goodwin advised Advanced Medical Solutions Group plc with a team including Sophie McGrath (Picture) and associate Ella Sharpley.

Involved fees earner: Sophie McGrath – Goodwin Procter; Ella Sharpley – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Advanced Medical Solutions Group plc;